NCT00620022

The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Phase III Randomized, Double-blind, Placebo-controlled, 2-period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 μg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

This study compared the effect of indacaterol (300 μg once daily \[od\]) on exercise endurance with that of placebo in patients with moderate to severe chronic obstructive pulmonary disease.

Conditions

• Chronic Obstructive Pulmonary Disease

Interventions

Type	Name	Description
DRUG	Indacaterol 300 μg	Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
DRUG	Placebo	Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.

Timeline

• Start date: 2008-04-01
• Primary completion: 2009-01-01
• Completion: 2009-01-01
• First posted: 2008-02-21
• Last updated: 2011-08-17
• Results posted: 2011-08-17

Locations

20 sites across 6 countries: United States, Belgium, Canada, Denmark, Italy, Spain